Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Merryman, Reid W., Carreau, Nicole A., Advani, Ranjana H., Spinner, Michael A., Herrera, Alex F., Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad, Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven M., Barta, Stefan K., Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin A., Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali M., Godfrey, James, Chavez, Julio, Cohen, Jonathan B., Troxel, Andrea B., Diefenbach, Catherine, Armand, Philippe
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Assuntos:
Brief Communications
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288660/
https://ncbi.nlm.nih.gov/pubmed/32275786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0040
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares